Montana’s rules governing state-licensed clinics that sell treatments the Food and Drug Administration has not approved took effect at the end of July, and the first review boards are now organizing to begin clearing therapies for sale.
The framework makes Montana the first state to license commercial facilities to recommend and administer experimental drugs, biologics, and devices to paying patients, under a law signed last year. The only federal milestone a treatment must clear is Phase I of clinical testing, the stage designed to check basic safety in a small number of people. It is not designed to show that anything works.
That distinction is the entire story for patients and families. A Montana license tells you a facility met state operating standards. It does not tell you a therapy is effective, and no one at the state level has evaluated whether it is.
Phase I Safety Testing Is a Low Bar to Clear
Under Senate Bill 535, signed by Governor Greg Gianforte in May 2025, an experimental treatment is one that has completed Phase I of an FDA-approved clinical trial and either remains under investigation or has a documented safety record, but has not received full FDA approval. Phase I trials typically enroll a few dozen participants and are designed to identify tolerable doses and detect obvious toxicity. Most drug candidates that clear Phase I never go on to approval because later, larger trials are where effectiveness is actually tested and where most candidates fail.
The Montana Department of Public Health and Human Services published 25 proposed rules implementing the law in April, held a hearing at the end of that month, and closed public comment in May. The final rulemaking took effect July 25, 2026. The rules cover center governance, staffing, patient protections, treatment oversight, adverse event reporting, and facility standards, and they distinguish between outpatient and inpatient experimental treatment centers.
The law also creates experimental treatment review boards, which are meant to evaluate protocols before licensed clinics offer them. Writing on the adoption of the rules, one participant told Longevity. Technology that “after more than a year of waiting, it’s finally here,” describing plans to submit board credentials immediately and begin protocol reviews within days.
A State License Is Not a Safety or Efficacy Finding
Montana’s law is a departure from both existing pathways patients might recognize.
The federal Right to Try Act of 2018 applies only to people with life-threatening conditions who have exhausted approved options. The FDA’s expanded access program, sometimes called compassionate use, requires agency review and physician oversight for each request. Montana broadened its own right-to-try law in 2023 beyond terminally ill patients and then, with SB 535, built a licensing and commercial structure on top of that opening. Licensed centers may recommend and administer experimental treatments for compensation. Patients must have considered approved options, received a provider recommendation, and given informed consent.
Supporters argue this creates supervision where none existed. People already travel abroad for unproven stem cell, gene and peptide therapies, often to clinics with no meaningful oversight at all, and the Montana framework at least requires licensing, informed consent, adverse event reporting and independent protocol review.
Critics are not persuaded that structure substitutes for evidence. Aaron Kesselheim, a Harvard Medical School professor of medicine who studies drug regulation, told MIT Technology Review that “I would be concerned” about selling unproven treatments without FDA oversight. The same reporting noted that early commercial interest has come substantially from oncology and neurodegenerative disease, not only from the longevity investors who drove the legislation.
Neither position is settled by the rules taking effect. What is settled is the regulatory fact: no federal agency has judged these products to be effective, and Montana’s licensing process does not attempt to do so.
The oversight the rules do impose is real but narrow. A summary of the draft framework prepared for industry describes governance, staffing, and physical plant standards; written patient agreements documenting anticipated costs and consent; and requirements for treatment oversight and adverse event reporting. Those are operational safeguards. None of them generate evidence of effectiveness, and none of them substitute for the later-stage trials that determine whether a therapy actually helps.
Costs Fall Entirely on the Patient
Insurance does not cover experimental treatments obtained this way. Neither Medicare nor commercial plans cover therapies that lack FDA approval, and patients should assume the full cost is out of pocket, including travel, lodging, and any follow-up care.
There is one narrow offset written into the law. Licensed centers must dedicate 2 percent of their net annual profits toward improving access to experimental treatments for Montana residents. That provision benefits Montana residents, not visitors traveling in.
Complications create a second financial exposure. If a treatment causes an adverse event, the resulting emergency care, hospitalization, or long-term treatment is a separate matter from the experimental therapy itself, and coverage for those consequences can become contested. Patients considering this route should ask, in writing, who is responsible for costs if something goes wrong.
Anyone weighing a Montana clinic can ask a treating oncologist, neurologist, or primary care physician to review the specific protocol first. Patients should also check whether the same therapy is available through a registered clinical trial, where treatment is typically provided at no charge and outcomes are systematically tracked.
The Questions Regulators Have Not Answered Yet
Several things remain genuinely unknown. No public data yet show how many centers will be licensed, which therapies will clear review boards, or what adverse events will be reported. The law requires oversight and adverse event reporting, but it is not clear whether that data will be published in a form patients can evaluate.
It is also unclear how the FDA will respond. The agency retains authority over drug manufacturing and interstate commerce, and the relationship between a state licensing scheme and federal enforcement has not been tested in court.
MedicalDaily will track the first licensed centers, the therapies approved for sale, and any published adverse event data. For now, the practical guidance is unglamorous: a state license is a business permit, not a verdict on whether a treatment helps.
Key Questions Answered
What did Montana actually do? It created a state licensing system for clinics that sell and administer treatments that have completed Phase I clinical testing but lack full FDA approval. The implementing rules took effect July 25, 2026.
Does a Montana license mean a treatment is safe or effective? No. It means a facility met state operating requirements. Phase I testing checks basic safety in small groups and is not designed to demonstrate that a treatment works.
Who can receive these treatments? Access is not limited to people at the end of life. Patients must have evaluated approved options, received a provider recommendation, and given informed consent.
Will insurance pay for it? No. Treatments without FDA approval are not covered by Medicare or commercial insurance. Patients should expect to pay the full cost, plus travel.
How is this different from a clinical trial? In a registered trial, treatment is usually provided at no cost, outcomes are systematically collected, and there is federal oversight. Under this framework, patients pay a licensed business.
What should someone ask before traveling to Montana for treatment? Ask which Phase I data exist, whether the same therapy is available in a registered trial, who is financially responsible if complications occur, and have a treating physician review the protocol.
Is the FDA challenging this? The agency has not announced enforcement action related to the framework. How federal authority interacts with a state licensing scheme has not been tested in court.
